期刊
MOLECULES
卷 27, 期 21, 页码 -出版社
MDPI
DOI: 10.3390/molecules27217311
关键词
HMGB1; RAGE; inflammation; inhibitors; TLRs
资金
- National Institutes of Health, USA [R01 HL144125, R01 HL147662]
In this article, the authors critically review the structural and functional mechanism of HMGB1 and RAGE in mediating inflammatory processes. They also summarize the recent therapeutic approaches that target the communication between HMGB1 and RAGE using small molecules, as well as their clinical progression in treating various inflammatory disorders. The article highlights the gaps in knowledge and future directions for the therapeutic potential of key molecules in HMGB1/RAGE signaling in inflammatory diseases.
High mobility group box 1 (HMGB1) is a nuclear protein that can interact with a receptor for advanced glycation end-products (RAGE; a multi-ligand immunoglobulin receptor) and mediates the inflammatory pathways that lead to various pathological conditions, such as cancer, diabetes, neurodegenerative disorders, and cardiovascular diseases. Blocking the HMGB1/RAGE axis could be an effective therapeutic approach to treat these inflammatory conditions, which has been successfully employed by various research groups recently. In this article, we critically review the structural insights and functional mechanism of HMGB1 and RAGE to mediate inflammatory processes. More importantly, current perspectives of recent therapeutic approaches utilized to inhibit the communication between HMGB1 and RAGE using small molecules are also summarized along with their clinical progression to treat various inflammatory disorders. Encouraging results are reported by investigators focusing on HMGB1/RAGE signaling leading to the identification of compounds that could be useful in further clinical studies. We highlight the current gaps in our knowledge and future directions for the therapeutic potential of targeting key molecules in HMGB1/RAGE signaling in the pathophysiology of inflammatory diseases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据